Ipamorelin

Ipamorelin (Ala-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide belonging to the growth hormone releasing peptide (GHRP) class, first described in the late 1990s by researchers at Novo Nordisk. It was developed as part of ongoing efforts to find selective, orally or parenterally administrable GH secretagogues. Unlike earlier generation GHRPs — GHRP-2 and GHRP-6 in particular — ipamorelin was specifically engineered to activate the ghrelin receptor (GHS-R1a) in the pituitary with high selectivity, producing GH release without the off-target activation of adrenocorticotropic hormone (ACTH), cortisol, or prolactin pathways that complicated earlier compounds. This selectivity profile is the primary reason ipamorelin attracted sustained research interest and remains among the most widely studied GHRPs in preclinical and limited clinical contexts.

The mechanism of action centers on ipamorelin's agonism at the growth hormone secretagogue receptor (GHS-R1a), located in the pituitary gland and hypothalamus. Binding at this receptor triggers a signaling cascade that results in pulsatile release of endogenous GH. Importantly, this release remains subject to the body's own somatostatin-mediated negative feedback, meaning it preserves the pulsatile, physiological pattern of GH secretion rather than producing sustained supraphysiological elevation. Research also suggests ipamorelin acts via partial ghrelin-pathway overlap, which may contribute to modest appetite signaling in some subjects, though this effect appears substantially weaker than that seen with GHRP-6. Downstream, elevated GH stimulates IGF-1 production from the liver, and it is largely through the IGF-1 axis that the compound's proposed anabolic and recovery-associated effects are thought to operate in animal models.

The evidence base for ipamorelin is meaningful but must be parsed carefully by study type. In animal models — primarily rodent studies — research has demonstrated significant GH and IGF-1 elevation, preservation of lean body mass, accelerated bone mineral density recovery in osteoporotic models, and improvements in gut motility parameters. A notable area of preclinical research involved ipamorelin's potential effects on postoperative ileus, where animal studies showed promising gastrointestinal motility restoration. Novo Nordisk advanced a related ipamorelin-based compound into early human clinical trials for postoperative ileus (Phase II/III, early 2000s), with results showing statistically significant reductions in time-to-bowel-recovery in surgical patients. However, this program was ultimately discontinued before regulatory submission, and the compound never reached approval. Outside of this clinical program, robust human-controlled trial data on ipamorelin's effects on body composition, recovery, or longevity markers in healthy adults remains sparse. A substantial portion of the surrounding discourse draws on extrapolation from animal studies, mechanistic inference, and self-reported user data from online communities — none of which constitute clinical evidence. This content is provided for educational purposes only and does not constitute medical advice or a recommendation for human use.

Dosing ranges reported in published preclinical research and referenced in the limited clinical literature vary considerably. Animal studies have used doses ranging from approximately 1 mcg/kg to 300 mcg/kg depending on endpoint studied. In the human postoperative ileus trials, IV administration protocols were used in controlled inpatient settings — not directly translatable to the subcutaneous research-chemical context in which ipamorelin is most commonly discussed. Anecdotal user reports in biohacking and bodybuilding communities most frequently reference doses of 200–300 mcg administered subcutaneously two to three times per day, often in combination with a GHRH analog such as CJC-1295, though this combination protocol has not been validated in controlled human trials. All dosing information here is reported from research and anecdotal contexts only and does not constitute a dosing recommendation under any circumstances. Individuals should not self-administer research chemicals.

Regarding legal status: in the United States, ipamorelin is not FDA-approved for any indication and is classified as a research chemical. It is not a DEA-scheduled controlled substance, but its sale for human consumption is prohibited under FDA regulations. It has appeared on the World Anti-Doping Agency (WADA) prohibited list as a peptide hormone. In the UK, ipamorelin sits in a regulatory grey zone as an unlicensed medicine; supply for human use without a prescription is prohibited under the Human Medicines Regulations 2012. In Australia, it is classified as a Schedule 4 substance (prescription-only) under the TGA framework, making its supply or possession without prescription illegal. The EU does not have harmonized scheduling for research peptides, but most member states treat unlicensed peptides similarly to the UK framework. Researchers and prospective buyers should verify applicable laws in their jurisdiction before procurement. From a sourcing standpoint, credible vendors should provide independently verified Certificates of Analysis (COA) from third-party laboratories showing HPLC purity (ideally ≥98%), mass spectrometry confirmation of molecular identity, and absence of common contaminants including bacterial endotoxins. Lyophilized powder is the standard commercial form; reconstituted solutions require bacteriostatic water and refrigerated storage.